

ASX/Media Release  
11 June 2013

## Compumedics Successfully Concludes Funding Activities and Secures US\$1 million Neurology Business in the US

- BIBBY Financial Services has provided Compumedics with a further short-term \$0.4m working capital facility to speed up the production and shipment of almost \$10m of sales orders currently on-hand.
- Compumedics has secured another significant LTEM site in the US, representing a combined US\$1m of new business to the Company

Compumedics Limited (ASX: CMP) is pleased to announce that it has finalised its current funding activities with the completion of a new short-term \$0.4million facility from BIBBY Financial Services as part of their overall \$2.5million facility with the Company. In addition the Company has secured a further short-term \$0.1million loan from its US-Based Director.

This additional short-term funding, together with the recent funding announcements, will provide the Company with sufficient working capital to enable it to ship and invoice a record \$10million backlog of sales orders, over the next few months. Clearing this backlog of sales orders will underpin the future growth of the Company, particularly in the long-term EEG monitoring (LTEM) market in the US and other key markets around the world.

To that end the Company has secured a new LTEM site in the US, confirming previous announcements to the market that its new neurology monitoring line will strengthen the company's future growth prospects.

**In commenting on funding activities and the new LTEM account, Dr. David Burton, Chairman and CEO of Compumedics said:**

"After a lengthy period where the Company has been actively seeking additional funds, I am pleased we have now largely completed those activities and will be able to completely refocus our energies on clearing the large back-log of \$10 million sales orders. This sheer volume and quantum of orders clearly validates the market's desire to purchase the leading-edge technology we produce for the diagnosis and monitoring of sleep and neurological disorders.

I am equally delighted to see that the Company continues to achieve its critical milestones in the development of its market position in LTEM and the wider neurological monitoring market. Winning these large accounts adds to the significant credibility the Company is developing in this market."

### About Compumedics

Compumedics Limited was founded in **1987** by current Chairman/CEO Dr. David Burton and today is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In **1987** Compumedics established Asia Pacific's first fully computerized sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. In **1995** the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, with over 8,000 participants scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States and Europe, its products are distributed in over 50 countries. In **1998** Compumedics was awarded the overall Australian Exporter of the Year. In **2000** Compumedics was listed on the Australian Stock Exchange. In **2002**, Compumedics acquired US-based **Neuroscan** - the world's leading supplier of instruments for brain research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. In **2003** Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. In **2004**, Compumedics acquired Germany-based **DWL Elektronische GmbH**, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In **2006**, Compumedics was awarded the Frost and Sullivan Technology Leadership award for its innovative Somte® recorder product. In **2007**, Compumedics and its Chairman were inducted into the Victorian Manufacturing Hall of Fame. In **2008** the DWL division received a top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics Compumedics sales have grown more than 4-fold from \$9 million (1999) to \$39 million (2008). In **2009** Compumedics was awarded a design award for its GRAEL® PSG/EEG premium laboratory-based product. In **2010** Compumedics was recognized by the Australian Innovation Government and Industry body as one of Australia's Top 100 Health Innovators through its world leading devices for sleep diagnostics. In **2011** Compumedics was selected as one of the 25 innovative Australian companies by the Australian Governments Department of Innovation, Industry, Science and Research (Industry).

For more information please visit: [www.compumedics.com](http://www.compumedics.com)

### For further information please contact:

**David Burton**, Chairman and CEO  
**Compumedics Limited**  
T: (03) 8420 7300  
M: 0414 384684  
E: [dburton@compumedics.co.au](mailto:dburton@compumedics.co.au)

**Rod North**, Managing Director,  
**Bourse Communications Pty Ltd**  
T: (03) 9510 8309,  
M: 0408 670 706  
E: [rod@boursecommunications.com.au](mailto:rod@boursecommunications.com.au)